‘BDS THIS’: Israel Makes ‘Exciting Breakthrough’ In Race For Coronavirus Vaccine

   DailyWire.com
An Israeli scientist works at a laboratory at the MIGAL Research Institute in Kiryat Shmona in the upper Galilee in northern Israel on February 27, 2020. - After 4 years of multi-disciplinary research funded by Israels Ministry of Science and Technology in cooperation with Israels Ministry of Agriculture, MIGAL has achieved a scientific breakthrough that will lead to the rapid creation of a vaccine against Coronavirus. This possibility was identified as a by-product of MIGALs development of a vaccine against IBV (Infectious Bronchitis Virus), a disease affecting poultry, whose effectiveness has been proven in pre-clinical trials carried out at the Veterinary Institute. MIGAL has now made required genetic adjustments to adapt the vaccine to COVID-19, the human strain of Coronavirus, and is working to achieve the safety approvals that will enable in-vivo testing, enable the initiation of production of a vaccine to counter the Coronavirus epidemic currently spreading throughout the world, which so far has claimed 2,666 lives.
JALAA MAREY/AFP via Getty Images

Israeli scientists are reportedly only a few weeks away from having developed the first vaccine to combat the coronavirus, which originated in China, and could have the vaccine available 90 days after that.

“Congratulations to MIGAL [The Galilee Research Institute] on this exciting breakthrough,” Science and Technology Minister Ofir Akunis said, according to The Jerusalem Post. “I am confident there will be further rapid progress, enabling us to provide a needed response to the grave global COVID-19 threat,” Akunis said, referring to the disease caused by the novel coronavirus.

A team of scientists at MIGAL had been working for years on a vaccine against an infectious bronchitis virus (IBV).

“Our basic concept was to develop the technology and not specifically a vaccine for this kind or that kind of virus,” said Dr. Chen Katz, MIGAL’s biotechnology group leader. “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis, causing the body to form antibodies against the virus.”

“Let’s call it pure luck,” Katz said. “We decided to choose coronavirus as a model for our system just as a proof of concept for our technology.”

The Jerusalem Post reported:

But after scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one, and that it uses the same infection mechanism, which increases the likelihood of achieving an effective human vaccine in a very short period of time.

“All we need to do is adjust the system to the new sequence,” Katz said. “We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands. Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.”

The CEO of MIGAL said that the company is moving as fast as it can to make the vaccine available to the public in the form of a highly accessible oral vaccination.

Online, pro-Israel voices quickly mocked those who support the anti-Semitic Boycott, Divestment, Sanctions (BDS) movement, which seeks to destroy the state of Israel.

Last month, The Jerusalem Post reported that Israeli scientists announced that they may have found a cure for cancer.

The Jerusalem Post reported:

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator. AEBi developed the SoAP platform, which provides functional leads to very difficult targets.

The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”

This report has been updated to include additional information.